Sartorius (SRT.DE) Stock Price

Sartorius Price

XETRA·CLOSED
186.00EUR+1.80 (+0.97 %)
Market closed

Over the last 19 years Sartorius grew revenue by 10.6% annually, reaching 3.54 B EUR. Earnings per share have grown at 37.1% per year over the last 16 years. For Sartorius, the net margin of 4.4% is down versus 12.4% a few years ago. At today's price the dividend yield works out to roughly 0.82%. The payout ratio is around 33% of earnings. The dividend has grown at 6.0% per year over the past 19 years. The consensus 12-month price target for Sartorius is 266.22 EUR, about 43.1% above where the stock trades today. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 25% above its 52-week low.

Sartorius stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Sartorius over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Sartorius stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Sartorius's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Sartorius Stock Price History
DateSartorius Price
8/7/2026186.00 EUR
8/5/2026184.20 EUR
8/4/2026183.80 EUR
7/31/2026177.00 EUR
7/30/2026179.60 EUR
7/29/2026177.40 EUR
7/28/2026169.00 EUR
7/27/2026170.00 EUR
7/24/2026174.00 EUR
7/23/2026171.20 EUR
7/22/2026179.40 EUR
7/21/2026175.20 EUR
7/20/2026189.60 EUR
7/17/2026198.40 EUR
7/16/2026196.40 EUR
7/15/2026198.80 EUR
7/14/2026198.20 EUR
7/13/2026197.80 EUR
7/10/2026195.60 EUR
7/9/2026188.80 EUR
7/8/2026183.80 EUR
7/7/2026186.80 EUR
7/6/2026187.80 EUR
7/3/2026187.40 EUR
7/2/2026190.60 EUR
7/1/2026190.00 EUR
6/30/2026187.80 EUR
6/29/2026185.00 EUR
6/26/2026184.20 EUR
6/25/2026189.40 EUR
6/24/2026178.40 EUR
6/23/2026175.80 EUR
6/22/2026176.80 EUR
6/19/2026177.20 EUR
6/18/2026173.70 EUR
6/17/2026183.50 EUR
6/16/2026183.80 EUR
6/15/2026185.20 EUR
6/12/2026184.20 EUR
6/11/2026186.20 EUR
6/10/2026189.20 EUR
6/9/2026187.80 EUR
6/8/2026186.00 EUR
6/5/2026193.00 EUR
6/4/2026195.00 EUR
6/3/2026187.60 EUR
6/2/2026192.60 EUR
6/1/2026192.20 EUR
5/29/2026193.20 EUR
5/28/2026181.80 EUR
5/27/2026187.40 EUR
5/26/2026183.80 EUR
5/25/2026187.60 EUR
5/22/2026188.60 EUR
5/21/2026186.60 EUR
5/20/2026182.20 EUR
5/19/2026181.20 EUR
5/18/2026178.60 EUR
5/15/2026164.80 EUR
5/14/2026168.40 EUR
5/13/2026169.80 EUR
5/12/2026168.60 EUR
5/11/2026172.60 EUR
5/8/2026173.40 EUR
5/7/2026178.20 EUR
5/6/2026177.80 EUR
5/5/2026176.20 EUR
5/4/2026172.80 EUR
4/30/2026174.60 EUR
4/29/2026168.60 EUR
4/28/2026170.20 EUR
4/27/2026175.00 EUR
4/24/2026174.40 EUR
4/23/2026166.40 EUR
4/22/2026185.60 EUR
4/21/2026192.00 EUR
4/20/2026187.00 EUR
4/17/2026188.20 EUR
4/16/2026177.80 EUR
4/15/2026179.00 EUR
4/14/2026180.00 EUR
4/13/2026171.40 EUR
4/10/2026168.80 EUR
4/9/2026167.40 EUR
4/8/2026174.40 EUR
4/7/2026168.40 EUR
4/2/2026164.46 EUR
3/27/2026166.52 EUR
3/26/2026169.60 EUR
3/25/2026170.80 EUR
3/24/2026167.78 EUR
3/23/2026167.40 EUR
3/20/2026165.49 EUR
3/19/2026166.91 EUR
3/17/2026175.18 EUR
3/16/2026164.85 EUR
3/13/2026166.97 EUR
3/12/2026172.91 EUR
3/11/2026171.95 EUR
3/10/2026178.28 EUR
3/9/2026171.40 EUR
3/6/2026181.01 EUR
3/5/2026185.53 EUR
2/27/2026190.40 EUR
2/26/2026192.20 EUR
2/25/2026192.37 EUR
2/23/2026190.06 EUR
2/20/2026195.61 EUR
2/19/2026192.07 EUR
2/18/2026189.75 EUR
2/17/2026182.50 EUR
2/16/2026181.04 EUR
2/13/2026183.68 EUR
2/12/2026180.09 EUR
2/11/2026182.20 EUR
2/10/2026185.78 EUR
2/9/2026184.56 EUR
2/6/2026186.80 EUR
2/5/2026186.21 EUR
2/4/2026191.17 EUR
2/3/2026184.83 EUR
2/2/2026186.69 EUR
1/30/2026188.87 EUR
1/29/2026192.53 EUR
1/28/2026193.00 EUR
1/27/2026197.69 EUR
1/26/2026201.72 EUR
1/23/2026200.79 EUR
1/22/2026201.46 EUR
1/21/2026199.00 EUR
1/19/2026195.21 EUR
1/16/2026203.44 EUR
1/15/2026198.22 EUR
1/14/2026201.05 EUR
1/13/2026200.74 EUR
1/12/2026200.12 EUR
1/9/2026202.60 EUR
1/8/2026205.51 EUR
1/7/2026206.12 EUR
1/6/2026204.87 EUR
1/5/2026193.96 EUR
1/2/2026191.72 EUR
12/30/2025191.80 EUR
12/29/2025188.20 EUR
12/23/2025188.84 EUR
12/22/2025186.93 EUR
12/19/2025186.37 EUR
12/18/2025184.40 EUR
12/17/2025183.71 EUR
12/16/2025183.30 EUR
12/15/2025185.80 EUR
12/12/2025190.34 EUR
12/11/2025193.15 EUR
12/10/2025197.00 EUR
12/9/2025194.40 EUR
12/8/2025196.75 EUR
12/5/2025198.34 EUR
12/3/2025199.30 EUR
12/2/2025193.64 EUR
12/1/2025198.31 EUR
11/28/2025190.40 EUR
11/27/2025191.84 EUR
11/26/2025189.49 EUR
11/25/2025183.40 EUR
11/24/2025181.40 EUR
11/21/2025175.22 EUR
11/20/2025177.01 EUR
11/19/2025175.50 EUR
11/18/2025175.87 EUR
11/17/2025181.25 EUR
11/14/2025178.78 EUR
11/13/2025183.86 EUR
11/12/2025183.80 EUR
11/11/2025181.27 EUR
11/10/2025177.58 EUR
11/7/2025176.43 EUR
11/6/2025178.00 EUR
11/5/2025179.00 EUR
11/4/2025183.38 EUR
11/3/2025190.86 EUR
10/31/2025191.00 EUR
10/30/2025191.28 EUR
10/29/2025192.20 EUR
10/28/2025192.79 EUR
10/27/2025193.37 EUR
10/24/2025192.80 EUR
10/23/2025190.79 EUR
10/22/2025193.60 EUR
10/21/2025190.81 EUR
10/20/2025188.94 EUR
10/17/2025185.49 EUR
10/16/2025187.12 EUR
10/15/2025172.92 EUR
10/14/2025169.50 EUR
10/13/2025173.27 EUR
10/10/2025174.37 EUR
10/9/2025175.45 EUR
10/8/2025175.05 EUR
10/7/2025184.62 EUR
10/6/2025183.91 EUR
10/3/2025181.03 EUR
10/2/2025179.00 EUR
10/1/2025173.25 EUR
9/30/2025161.40 EUR
9/29/2025159.40 EUR
9/26/2025158.60 EUR
9/25/2025161.40 EUR
9/24/2025167.68 EUR
9/23/2025170.45 EUR
9/22/2025174.25 EUR
9/19/2025174.20 EUR
9/18/2025170.06 EUR
9/17/2025163.85 EUR
9/16/2025163.10 EUR
9/15/2025160.00 EUR
9/12/2025159.40 EUR
9/11/2025158.80 EUR
9/10/2025163.80 EUR
9/9/2025161.83 EUR
9/8/2025158.78 EUR
9/5/2025158.00 EUR
9/4/2025156.00 EUR
9/3/2025162.23 EUR
9/2/2025163.18 EUR
9/1/2025166.69 EUR
8/29/2025160.60 EUR
8/28/2025159.78 EUR
8/27/2025161.74 EUR
8/26/2025161.19 EUR
8/25/2025160.40 EUR
8/22/2025160.94 EUR
8/21/2025162.21 EUR
8/20/2025162.62 EUR
8/19/2025162.28 EUR
8/18/2025160.20 EUR
8/15/2025161.24 EUR
8/14/2025162.23 EUR
8/13/2025161.87 EUR
8/12/2025156.05 EUR
8/11/2025149.60 EUR
8/8/2025149.00 EUR
8/7/2025148.36 EUR
Access this data via the Eulerpool API
Get Free API Key

Sartorius Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
3.40 B EUR
543.20 M EUR
205.20 M EUR
Jan 1, 2024
3.38 B EUR
437.20 M EUR
84.00 M EUR
Jan 1, 2025
3.54 B EUR
651.40 M EUR
154.90 M EUR
Jan 1, 2026 (e)
3.72 B EUR
706.78 M EUR
370.63 M EUR
Jan 1, 2027 (e)
4.08 B EUR
773.91 M EUR
444.83 M EUR
Jan 1, 2028 (e)
4.48 B EUR
849.23 M EUR
530.32 M EUR
Jan 1, 2029 (e)
4.92 B EUR
933.72 M EUR
619.91 M EUR
Jan 1, 2030 (e)
5.38 B EUR
1.02 B EUR
723.32 M EUR

Sartorius Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 7, 2026, 1:05 PM
 
REVENUEB EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB EUR
EBITB EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
1.301.401.571.832.343.454.173.403.383.543.724.084.484.925.386.49
16.708.0011.5416.6027.8847.7121.02-18.66-0.444.675.269.519.749.949.4120.55
48.5450.2851.2851.5351.6153.2952.6146.1645.0946.2446.2446.2446.2446.2446.2446.24
0.630.710.800.941.211.842.201.571.521.641.721.892.072.282.493.00
0.250.260.300.360.520.741.160.540.440.650.710.770.850.931.02–
19.0018.6619.1619.4422.4021.3127.8915.9912.9318.4018.9618.9618.9718.9618.97–
102.00114.00141.00218.00321.00426.00913.00205.0084.00154.00370.00444.00530.00619.00723.00825.00
-19.0511.7623.6854.6147.2532.71114.32-77.55-59.0283.33140.2620.0019.3716.7916.8014.11
1.500.450.500.610.350.701.251.430.731.520.730.740.74–––
41.51-70.0011.1122.00-42.62100.0078.5714.40-48.95108.22-51.971.37––––
68.9769.0968.2068.4268.6968.5768.4268.4269.0469.0569.0569.0569.0569.0569.0569.05
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Sartorius generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Sartorius retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Sartorius's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Sartorius has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Sartorius's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Sartorius stock margins

The Sartorius margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sartorius. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sartorius.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
53.31 %
21.33 %
12.38 %
Jan 1, 2022
52.61 %
27.88 %
21.87 %
Jan 1, 2023
46.15 %
16.00 %
6.04 %
Jan 1, 2024
45.09 %
12.93 %
2.48 %
Jan 1, 2025
46.26 %
18.41 %
4.38 %
Jan 1, 2026 (e)
46.26 %
18.98 %
9.95 %
Jan 1, 2027 (e)
46.26 %
18.98 %
10.91 %
Jan 1, 2028 (e)
46.26 %
18.98 %
11.85 %

Sartorius Stock Revenue, EBIT, Earnings per Share

The Sartorius earnings per share therefore indicates how much revenue Sartorius has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
50.30 EUR
10.73 EUR
6.23 EUR
Jan 1, 2022
61.02 EUR
17.01 EUR
13.35 EUR
Jan 1, 2023
49.63 EUR
7.94 EUR
3.00 EUR
Jan 1, 2024
48.97 EUR
6.33 EUR
1.22 EUR
Jan 1, 2025
51.24 EUR
9.43 EUR
2.24 EUR
Jan 1, 2026 (e)
54.00 EUR
10.24 EUR
5.37 EUR
Jan 1, 2027 (e)
59.13 EUR
11.21 EUR
6.45 EUR
Jan 1, 2028 (e)
64.88 EUR
12.30 EUR
7.69 EUR

Sartorius business model & stock analysis

Sartorius AG is a globally operating company specializing in the development and manufacturing of laboratory equipment and process technologies. It was founded in 1870 by industrialist and entrepreneur Florenz Sartorius in Göttingen, Germany. The company initially focused on the sale of scales, weights, and measuring instruments but has since expanded and diversified its product line. Today, Sartorius AG is a world leader in the bioprocessing and laboratory equipment sectors and is known for its innovative products and procedures. The company's business model revolves around the development of high-tech products for applications in biotechnology, pharmaceuticals, and the food industry. It operates in two main business segments: Bioprocess Solutions and Lab Products & Services. The Bioprocess Solutions segment provides solutions and services for biopharmaceutical production, including filtration, fermentation, fluid management, and cell cultures. The products in this segment are typically disposable consumables used in the production of biopharmaceutical agents. The Lab Products & Services segment offers a wide range of laboratory equipment, from scales and microbiology equipment to ultrafiltration devices. These instruments are used by researchers and scientists in academic, industrial, and pharmaceutical laboratories worldwide. Furthermore, an important part of Sartorius' portfolio includes bioreactors and fermenters. These specialized devices are used for cultivating cells and microorganisms and are particularly important in biotechnology and vaccine production. Sartorius has established itself as a leader in this field through its innovative and high-performance products. In addition to the pharmaceutical, biotechnology, and laboratory sectors, Sartorius is also active in environmental technology. The company provides products and services for water analysis and purification, which are in demand in industries such as pharmaceuticals, food production, and environmental analysis due to their precise and reliable results. Sartorius demonstrates its innovation through the use of technologies such as machine learning and artificial intelligence. For example, the company offers the "Ambr" solution for fast and reliable modeling of production scenarios for biopharmaceutical agents. Machine learning techniques are employed to generate more data and make better decisions. Overall, Sartorius AG is a global company with a wide range of products and services for the biotechnology, pharmaceutical, chemical, and food industries. The company's innovation is evident in its continuous advancement of procedures, technologies, and products. With a strong market position and clear strategic direction, Sartorius will continue to be an important player in the industry and support the work of researchers and scientists worldwide with its high-performance products.

Sartorius SWOT Analysis

Strengths

Sartorius AG has established a reputable brand image in the industry, known for its high-quality products and innovative solutions. This enables the company to attract and retain a loyal customer base.

Sartorius AG offers a wide range of products that cater to various industries, including biotechnology, pharmaceutical, and laboratory equipment. This diversification helps the company to capture multiple revenue streams and reduce dependence on a single market.

The company heavily invests in research and development activities, enabling it to continuously introduce new and advanced products to the market. This fosters innovation and keeps Sartorius AG at the forefront of technological advancements.

Weaknesses

Sartorius AG's financial performance is influenced by global economic conditions and market fluctuations. During economic downturns, the demand for its products may decrease, impacting the company's revenue and profitability.

While Sartorius AG has a strong brand reputation, it may have limited market presence compared to some of its competitors. This may restrict its market share and potential growth opportunities in certain geographic regions.

Opportunities

The biopharmaceutical industry is experiencing significant growth, driven by factors such as increasing research activities, rising investments in healthcare, and advancements in personalized medicine. Sartorius AG can capitalize on this trend by providing specialized equipment and solutions to meet the growing demand.

Expansion into emerging markets, such as Asia-Pacific and Latin America, can provide Sartorius AG with new growth opportunities. These regions have a growing biotechnology and pharmaceutical sector, creating a potential market for the company's products.

Threats

The industry in which Sartorius AG operates is highly competitive, with numerous players vying for market share. The company faces competition from both established companies and new entrants, which can pose challenges to its market position.

The biopharmaceutical industry is subject to strict regulatory requirements, and non-compliance can lead to penalties and reputational damage. Sartorius AG needs to continually ensure compliance with regulations and industry standards to mitigate legal risks.

Sartorius Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Sartorius historical P/E ratio, EBIT multiple, and P/S ratio

Sartorius annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Sartorius shares outstanding

The number of shares of Sartorius was 69.05 M in 2025. This indicates how many shares Sartorius is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
68.57 M Stocks
Jan 1, 2022
68.42 M Stocks
Jan 1, 2023
68.42 M Stocks
Jan 1, 2024
69.04 M Stocks
Jan 1, 2025
69.05 M Stocks
Jan 1, 2026 (e)
69.05 M Stocks
Jan 1, 2027 (e)
69.05 M Stocks
Jan 1, 2028 (e)
69.05 M Stocks

Sartorius stock splits

In Sartorius's history, there have been no stock splits.

Sartorius Dividend History

28 years of dividend payments

YearAnnual DividendYoY ChangePayments
20260.73EURYTD—1×
Mar 27, 20260.73EUR↓ 7.6%1/1
20251.52EUR↑ 108.2%2×
Mar 28, 20250.73EUR 0.0%1/2
Mar 31, 20250.79EUR↑ 8.2%2/2
20240.73EUR↓ 49.0%1×
20231.43EUR↑ 14.4%1×
20221.25EUR↑ 78.6%1×
20210.70EUR↑ 100.0%1×
20200.35EUR↓ 42.6%1×
20190.61EUR↑ 22.0%1×
20180.50EUR↑ 11.1%1×
20170.45EUR↓ 70.0%1×

Sartorius dividend history and estimates

In 2025, Sartorius paid a dividend amounting to 1.52 EUR. Dividend means that Sartorius distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
0.70 EUR
0.00 EUR
Jan 1, 2022
1.25 EUR
0.00 EUR
Jan 1, 2023
1.43 EUR
0.00 EUR
Jan 1, 2024
0.73 EUR
0.00 EUR
Jan 1, 2025
1.52 EUR
0.00 EUR
Jan 1, 2026
0.73 EUR
0.00 EUR
Jan 1, 2027 (e)
0.00 EUR
0.74 EUR
Jan 1, 2028 (e)
0.00 EUR
0.74 EUR

Sartorius dividend payout ratio

In 2025, Sartorius had a payout ratio of 32.54%. The payout ratio indicates the percentage of the company's profits that Sartorius distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
11.24 %
Jan 1, 2022
9.37 %
Jan 1, 2023
47.68 %
Jan 1, 2024
60.00 %
Jan 1, 2025
32.54 %
Jan 1, 2026 (e)
13.59 %
Jan 1, 2027 (e)
11.41 %
Jan 1, 2028 (e)
9.66 %

Current Sartorius forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
75.00 % (6)
Hold
25.00 % (2)
Sell
0.00 % (0)
12M Price Target
266.22
Last Price
187.20
Currency
EUR
12M Return Potential
42.21 %
LTM Return
0 %

Sartorius Analyst Rating Actions

DateFirmActionRatingReliability
11/10/2020
KeyBanc
KeyBanc
MaintainedSector WeightEqual Weight49
11/10/2020
Keybanc
Keybanc
MaintainedSector WeightEqual Weight49

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Sartorius Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
1/24/20242.86EUR-959.50 MEUR-2023 Q4
2/15/20231.71EUR-906.39 MEUR-2022 Q4
10/19/20222.30EUR-991.65 MEUR-2022 Q3
7/21/20222.28EUR-977.44 MEUR-2022 Q2
4/21/20222.22EUR-950.04 MEUR-2022 Q1
10/20/2020-EUR-484.15 MEUR-2020 Q3
4/21/2020-EUR-503.44 MEUR-2020 Q1
10/22/20190.77EUR-468.02 MEUR-2019 Q3
7/19/20190.72EUR-433.40 MEUR-2019 Q2
4/18/20190.59EUR-395.85 MEUR-2019 Q1

EESG©

Eulerpool ESG Scorecard© for the Sartorius stock

91/100
97
Environment
99
Social
77
Governance
E

Environment

20
Scope 1 - Direct Emissions20,355
Scope 2 - Indirect emissions from purchased energy51,872
Scope 3 - Indirect emissions within the value chain645,033
Total CO₂ emissions72,227
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees39
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Sartorius shareholder structure

% Name
0.14206%
ProfitlichSchmidlin AG
ProfitlichSchmidlin AG
0.12284%
Carmignac Gestion
Carmignac Gestion
0.01328%
Carmignac Gestion Luxembourg SA
Carmignac Gestion Luxembourg SA
0.01311%
DWS Investment GmbH
DWS Investment GmbH
0.00662%
BlackRock Investment Management (UK) Ltd.
BlackRock Investment Management (UK) Ltd.
0.00435%
PEH Wertpapier AG
PEH Wertpapier AG

Sartorius Beneficial Ownership Filings (SEC 13D/G)

Free Float
4.4%
Float Shares
-
Shares Outstanding
-

Sartorius Executives and Management Board

16 members · avg. age 58 · 38 % women

FF

Dr. Florian Funck (53)

Chief Financial Officer, Member of the Executive Board

1.76 M EUR

Management

JK

Dr. Joachim Kreuzburg (59)

Chairman of the Executive Board, Chief Executive Officer

1.58 M EUR
MG

Dr. Michael Grosse (57)

Chief Executive Officer, Member of the Executive Board

–

Board of Directors

RF

Dr. Rene Faber (49)

Member of the Executive Board, Head - Bioprocess Solutions Division

1.97 M EUR
AG

Dr. Alexandra Gatzemeyer (45)

Member of the Executive Board, Head - Lab Products & Services Division

1.53 M EUR
LK

Dr. Lothar Kappich (68)

Chairman of the Supervisory Board, Shareholder Representative · since 2007

284,000.00 EUR
PT

Prof. Dr. Klaus Truetzschler (76)

Independent Member of the Supervisory Board, Shareholder Representative

189,000.00 EUR
DM

Mr. Dietmar Mueller (48)

Member of the Supervisory Board, Employee Representative

118,000.00 EUR
AB

Ms. Annette Becker (60)

Member of the Supervisory Board

117,000.00 EUR

Sartorius Supply Chain

Sartorius Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
10 companies
#Nameβ 1YTrend
1
Bio-Rad Laboratories A
Supplier·Customer·Life Sciences Tools & Services·US
0.77
0.81
0.90
0.96
0.91
0.93
0.71
2
Sartorius Stedim Biotech
Supplier·Customer·Life Sciences Tools & Services·FR
0.64
0.56
0.80
0.95
0.91
0.93
0.83
3
Waters
Supplier·Customer·Life Sciences Tools & Services·US
0.44
-0.02
0.11
0.77
0.89
0.82
0.76
4
Evotec
Supplier·Customer·Life Sciences Tools & Services·DE
-0.09
-0.36
0.24
0.89
0.74
0.81
—
5
Eiwa
Customer·Electronic Equipment, Instruments & Components·JP
0.58
0.40
0.65
-0.47
0.51
0.67
—
#Nameβ 1YTrend
1
908 Devices
Supplier·Electronic Equipment, Instruments & Components·US
0.09
-0.06
0.49
0.70
0.76
—
—
2
Adimmune
Customer·Biotechnology·TW
0.68
-0.12
0.32
0.74
0.66
-0.39
—

Frequently asked questions about Sartorius

The business model of Sartorius AG, a renowned company in the stock market, revolves around providing innovative and high-quality products and solutions for biopharmaceutical research and manufacturing. Sartorius AG specializes in the fields of laboratory instruments, consumables, and services, catering to the needs of pharmaceutical and biotech companies worldwide. With a strong focus on bioprocessing technologies, Sartorius AG enables its customers to efficiently develop and produce medications. Through continuous advancements in technology and a customer-oriented approach, Sartorius AG has established itself as a leading supplier in the life science industry, contributing significantly to the advancement of healthcare.

Sartorius AG is primarily active in the life sciences industry.

The main competitors of Sartorius AG in the market include Thermo Fisher Scientific, Danaher Corporation, and Merck KGaA.

Sartorius AG is a renowned German company with a rich history and background. Founded in 1870, Sartorius specializes in manufacturing and distributing laboratory and process technologies. With a strong focus on biopharmaceutical research and production, the company is widely recognized for its innovative solutions in filtration, weighing, and separation technologies. Sartorius AG has expanded globally and established a strong presence in over 110 countries, catering to a diverse range of industries such as food, healthcare, and biotechnology. With a legacy of excellence, Sartorius AG continues to be a leading provider of cutting-edge scientific instruments and services.

Sartorius AG, a renowned company in the stock market, has accomplished several significant milestones. With a strong focus on precision and excellence, Sartorius AG has achieved remarkable growth and recognition over the years. Some noteworthy achievements include expanding its global presence by establishing subsidiaries and offices in key markets, continuously innovating and launching breakthrough products, and solidifying strategic partnerships with leading industry players. Sartorius AG has also received prestigious awards for its cutting-edge technology and outstanding performance in the life sciences and biopharmaceutical sectors. Through its dedication to quality and customer satisfaction, Sartorius AG has established itself as a trusted and forward-thinking company in the stock market.

Sartorius AG, a leading biotechnology and laboratory equipment provider, is primarily present in various countries and regions worldwide. The company's global footprint extends across major markets, including North America, Europe, Asia-Pacific, and Latin America. With its headquarters in Goettingen, Germany, Sartorius AG maintains a strong presence in its home country, serving as a hub for research and production. Moreover, the company has established subsidiaries and offices in key countries such as the United States, China, Japan, France, and many others, enabling Sartorius AG to cater to a diverse customer base and foster strategic collaborations on a global scale.

Sartorius AG represents a set of values and corporate philosophy focused on innovation, quality, and sustainability. As a leading international laboratory and pharmaceutical equipment provider, Sartorius AG ensures customer satisfaction by continually developing cutting-edge technologies and maintaining the highest standards of product excellence. With a strong commitment to sustainability, the company aims to create long-term value for its stakeholders, including customers, employees, and investors. Sartorius AG's dedication to ethical practices, collaboration, and social responsibility underpins its mission to contribute to the progress of science and the betterment of society.

Analysts currently set an average price target of 302.69 EUR for the Sartorius stock (median: 266.22 EUR), implying +61.7 % versus the latest price. The consensus is based on 8 analyst ratings.

Sartorius Analyst Price Targets 2026

8 analysts currently rate the Sartorius stock: 6 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Sartorius to generate revenue of 3.72 B EUR and earnings per share of 5.37 EUR.

Sartorius Analyst Price Targets 2026

The Sartorius share (SRT.DE) is listed on 10 stock exchanges, including: XETRA (SRT.DE), Frankfurt (SRT.F), München (SRT.MU), Düsseldorf (SRT.DU), Hamburg (SRT.HM), London (0NIQ.L), London (0NIQ.L), SIX (Zürich) (SRT.SW).

Sartorius AG is a global provider of innovative technologies and solutions for biopharmaceuticals, as well as for laboratory, food, and environmental applications. The company has two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions supplies the necessary technologies and products for the production of biopharmaceuticals, including filtration systems, disposable bioreactors, peristaltic pumps, and process control systems. Lab Products & Services offers innovative laboratory instrumentation and consumables for research, development, quality assurance, and control. The company is known for its use of disposable systems in biopharmaceuticals, which ensure process sterility and reduce cleaning and validation efforts. The company is focused on innovation and customer orientation to remain competitive in a rapidly changing global market. It invests in research and development to offer the most future-proof and efficient technologies and solutions to its customers. Overall, Sartorius operates in a growing industry driven by an increase in global patient data, the rising demand for personalized medicine, and the need for more efficient production processes.

The expected revenue of Sartorius is 3.72 B EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Sartorius is 370.63 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Sartorius is currently 34.65. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Sartorius stock.

The price-to-sales ratio (P/S) of Sartorius is currently 3.45. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Sartorius stock.

The Eulerpool Quality Score for Sartorius is 5/10.

The ISIN of Sartorius is DE0007165607. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Sartorius is 716560. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Sartorius is SRT.DE. The ticker symbol is used to trade Sartorius shares on the stock exchange.

Over the past 12 months, Sartorius paid a dividend of 1.52 EUR . This corresponds to a dividend yield of about 0.82 %. For the coming 12 months, Sartorius is expected to pay a dividend of 0.74 EUR.

The current dividend yield of Sartorius is 0.82 %.

Sartorius pays a dividend, distributed in the months of , , , .

Sartorius paid dividends every year for the past 27 years.

For the upcoming 12 months, dividends amounting to 0.74 EUR are expected. This corresponds to a dividend yield of 0.40 %.

Sartorius is assigned to the 'Health' sector.

To receive the latest dividend of Sartorius from amounting to 0.73 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Sartorius distributed 0.73 EUR as dividends.

The dividends of Sartorius are distributed in EUR.

All fundamentals and in-depth analysis of Sartorius

Our stock analysis for Sartorius stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sartorius. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Sartorius Stock
Sartorius Revenue→
Sartorius Stock
Sartorius Net Income→
Sartorius Stock
Sartorius P/E→
Sartorius Stock
Sartorius P/S→
Sartorius Stock
Sartorius EBIT→
Sartorius Stock
Sartorius Dividend→
Sartorius Stock
Sartorius Directors Dealings→
Sartorius Stock
Sartorius Stocks→
Sartorius Stock
Sartorius Market capitalization→
Sartorius Stock
Sartorius Debt→
Sartorius Stock
Sartorius Liabilities→
Sartorius Stock
Sartorius Equity→
Sartorius Stock
Sartorius AAQS→
Sartorius Stock
Sartorius Employees→
Sartorius Stock
Sartorius ROE→
Sartorius Stock
Sartorius ROA→
Sartorius Stock
Sartorius ROCE→
Sartorius Stock
Sartorius News→
Sartorius Stock
Sartorius Analyst Price Targets→

Health Stocks

Sartorius Stedim BiotechSareum HoldingsSativa Growth InternationalSarepta TherapeuticsSaudi Chemical Holding Company SJSCSarana Meditama Metropolitan Tbk PTSaudi Pharmaceutical Industries and Medical Appliances Corp SPIMACO ADDWAEIH SJSCSANUWAVE HealthSavaraSanthera Pharmaceuticals HoldingSavior LifetecSanten Pharmaceutical CoAll Stocks A–Z →